Executive Chairman of Actinium Pharmaceuticals discusses his company’s positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for Actinium, an Acute Myeloid Leukemia (AML) drug.
